Gender Difference in the Prognostic Role of Interleukin 6 in Oral Squamous Cell Carcinoma

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Chen, Chih Jung ^a,b,c   Sung, Wen Wei ^a   Lin, Yueh Min ^b,c   Chen, Mu Kuan ^a,b   Lee, Ching Hsiao ^c   Lee, Huei ^a   Yeh, Kun Tu ^a,b   Ko, Jiunn Liang ^a,d  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c JEN TEH JUNIOR COLLEGE OF MEDICINE   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PATIENT ASSESSMENT; PROTEIN EXPRESSION; SEX DIFFERENCE; TUMOR CELL; TUMOR DIFFERENTIATION;

AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION; HUMANS; INTERLEUKIN-6; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; SEX CHARACTERISTICS; SURVIVAL RATE;

EID: 84869756365     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050104     Document Type: Article

References (35)

1. Argiris A, Karamouzis MV, Raben D, Ferris RL, (2008) Head and neck cancer. Lancet 371: 1695-1709.
2. Barnes L, Eveson JW, Reichart P, Sidransky D (2005) World health organization classification of tumours. pathology & genetics. head and neck tumours. Lyon: IARC Press.
3. Chung TT, Pan MS, Kuo CL, Wong RH, Lin CW, et al. (2011) Impact of RECK gene polymorphisms and environmental factors on oral cancer susceptibility and clinicopathologic characteristics in taiwan. Carcinogenesis 32: 1063-1068.
4. Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, et al. (1995) Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in taiwan. J Oral Pathol Med 24: 450-453.
5. Chiang CT, Chang TK, Hwang YH, Su CC, Tsai KY, et al. (2011) A critical exploration of blood and environmental chromium concentration among oral cancer patients in an oral cancer prevalent area of taiwan. Environ Geochem Health 33: 469-476.
6. Kishimoto T, (1989) The biology of interleukin-6. Blood 74: 1-10.
7. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G, (2006) Inflammation and cancer: How hot is the link? Biochem Pharmacol 72: 1605-1621.
8. Schafer ZT, Brugge JS, (2007) IL-6 involvement in epithelial cancers. J Clin Invest 117: 3660-3663.
9. Knupfer H, Preiss R, (2010) Serum interleukin-6 levels in colorectal cancer patients-a summary of published results. Int J Colorectal Dis 25: 135-140.
10. Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR, (2011) A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther 11: 1663-1668.
11. Ravishankaran P, Karunanithi R, (2011) Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J Surg Oncol 9: 18.
12. Klein SC, Jucker M, Abts H, Tesch H, (1995) IL6 and IL6 receptor expression in burkitt's lymphoma and lymphoblastoid cell lines: Promotion of IL6 receptor expression by EBV. Hematol Oncol 13: 121-130.
13. Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, et al. (1993) Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced hodgkin's disease and with B symptoms. Cancer Res 53: 2118-2122.
14. Lin MT, Lin BR, Chang CC, Chu CY, Su HJ, et al. (2007) IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. Int J Cancer 120: 2600-2608.
15. Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, et al. (2009) High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer. 124: 2766-2770.
16. Paule B, Belot J, Rudant C, Coulombel C, Abbou CC, (2000) The importance of IL-6 protein expression in primary human renal cell carcinoma: An immunohistochemical study. J Clin Pathol 53: 388-390.
17. Thiounn N, Pages F, Flam T, Tartour E, Mosseri V, et al. (1997) IL-6 is a survival prognostic factor in renal cell carcinoma. Immunol Lett 58: 121-124.
18. Qian Y, Deng J, Xie H, Geng L, Zhou L, et al. (2009) Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signaling. J Cancer Res Clin Oncol 135: 379-386.
19. Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, et al. (2003) Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 63: 3560-3566.
20. Okamoto M, Hiura K, Ohe G, Ohba Y, Terai K, et al. (2000) Mechanism for bone invasion of oral cancer cells mediated by interleukin-6 in vitro and in vivo. Cancer 89: 1966-1975.
21. Nibali L, Fedele S, D'Aiuto F, Donos N, (2012) Interleukin-6 in oral diseases: A review. Oral Dis 18: 236-243.
22. Shinriki S, Jono H, Ota K, Ueda M, Kudo M, et al. (2009) Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res 15: 5426-5434.
23. Kurago ZB, Lam-ubol A, Stetsenko A, De La Mater C, Chen Y, et al. (2008) Lipopolysaccharide-squamous cell carcinoma-monocyte interactions induce cancer-supporting factors leading to rapid STAT3 activation. Head Neck Pathol 2: 1-12.
24. St John MA, Li Y, Zhou X, Denny P, Ho CM, et al. (2004) Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 130: 929-935.
25. Gasche JA, Hoffmann J, Boland CR, Goel A, (2011) Interleukin-6 promotes tumorigenesis by altering DNA methylation in oral cancer cells. Int J Cancer 129: 1053-1063.
26. Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, et al. (2008) Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 113: 750-757.
27. Wang YF, Chang SY, Tai SK, Li WY, Wang LS, (2002) Clinical significance of interleukin-6 and interleukin-6 receptor expressions in oral squamous cell carcinoma. Head Neck 24: 850-858.
28. SahebJamee M, Eslami M, AtarbashiMoghadam F, Sarafnejad A, (2008) Salivary concentration of TNFalpha, IL1 alpha, IL6, and IL8 in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 13: E292-5.
29. Chen CJ, Hsu LS, Lin SH, Chen MK, Wang HK, et al. (2012) Loss of nuclear expression of kruppel-like factor 4 is associated with poor prognosis in patients with oral cancer. Hum Pathol 43(7): 1119-1125.
30. Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell FM, et al. (2011) A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 29: 3567-3573.
31. Shinriki S, Jono H, Ueda M, Ota K, Ota T, et al. (2011) Interleukin-6 signalling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma. J Pathol 225: 142-150.
32. Nagata M, Fujita H, Ida H, Hoshina H, Inoue T, et al. (2003) Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis. Int J Cancer 106: 683-689.
33. Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, et al. (2003) Human papillomavirus and oral cancer: The international agency for research on cancer multicenter study. J Natl Cancer Inst 95: 1772-1783.
34. Termine N, Panzarella V, Falaschini S, Russo A, Matranga D, et al. (2008) HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: A meta-analysis (1988-2007). Ann Oncol 19: 1681-1690.
35. Yang YY, Koh LW, Tsai JH, Tsai CH, Wong EF, et al. (2004) Involvement of viral and chemical factors with oral cancer in taiwan. Jpn J Clin Oncol 34: 176-183.